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Abstract: ISO15189:2012 requires medical laboratories 
to document metrological traceability of their results. 
While the ISO17511:2003  standard on metrological 
traceability in laboratory medicine requires the use of 
the highest available level in the traceability chain, it 
recognizes that for many measurands there is no refer-
ence above the manufacturer’s selected measurement 
procedure and the manufacturer’s working calibrator. 
Some immunoassays, although they intend to measure 
the same quantity and may even refer to the same ref-
erence material, unfortunately produce different results 
because of differences in analytical selectivity as manu-
facturers select different epitopes and antibodies for the 
same analyte. In other cases, the cause is the use of ref-
erence materials, which are not commutable. The uncer-
tainty associated with the result is another important 
aspect in metrological traceability implementation. As 
the measurement uncertainty on the clinical samples is 
influenced by the uncertainty of all steps higher in the 
traceability chain, laboratories should be provided with 
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adequate and appropriate information on the uncer-
tainty of the value assignment to the commercial calibra-
tors that they use. Although the between-lot variation in 
value assignment will manifest itself as part of the long-
term imprecision as estimated by the end-user, informa-
tion on worst-case to be expected lot-lot variation has to 
be communicated to the end-user by the IVD provider. 
When laboratories use ancillary equipment that poten-
tially could have a critical contribution to the reported 
results, such equipment needs verification of its proper 
calibration and criticality to the result uncertainty could 
be assessed by an approach based on risk analysis, 
which is a key element of ISO15189:2012 anyway. This 
paper discusses how the requirement for metrological 
traceability as stated in ISO15189 should be met by the 
medical laboratory and how this should be assessed by 
accreditation bodies.
Keywords: metrological traceability; risk management.
Background
Results provided by medical laboratories have an impor-
tant role in medical decisions [1]. Because results are com-
pared to reference intervals, decision limits or with earlier 
results that may have been established elsewhere in the 
care process, it is important that results are equivalent 
(within stated specifications). Metrological traceability to 
a certified reference material and/or reference procedure 
should assure equivalence of patient results across time, 
space and measuring systems [2–8].
The ISO/IEC guide on International Vocabulary of 
Basic and General Terms in Metrology (VIM- 2012) [9] 
defines metrological traceability as: “property of a meas-
urement result whereby the result can be related to a refer-
ence through a documented unbroken chain of calibrations, 
each contributing to the measurement uncertainty”.
ISO 15189:2012, which specifies requirements for 
quality and competence in medical laboratories, requires 
laboratories to verify and document the metrological 
traceability of calibration of their measurement pro-
cedures [10]. Hence, accreditation to this standard by 
the national accreditation bodies requires verification 
whether this is done properly. The International Labora-
tory Accreditation Cooperation (ILAC) has issued a policy 
on the assessment of metrological traceability of labora-
tory results [11]. As national accreditation bodies that 
have signed the multilateral agreement between interna-
tional accreditation bodies have to comply with ILAC poli-
cies, the requirements of these policies are relevant to all 
parties involved as they are essential for harmonization of 
ISO15189 accreditation [12].
Ideally, measurement procedures are traceable to the 
International System of Units (SI), but for many measur-
ands in medical laboratories, this is not achievable. To 
cope with these specific challenges, specific ISO stand-
ards have been developed, i.e. ISO17511:2003 “In vitro 
diagnostic medical devices – Measurement of quanti-
ties in biological samples – Metrological traceability of 
values assigned to calibrators and control materials” [13] 
and ISO 18153:2003 “In vitro diagnostic medical devices 
– Measurement of quantities in biological samples – Met-
rological traceability of values for catalytic concentration 
of enzymes assigned calibrators and control materials” 
[14]. The ISO 17511  standard states that “in many cases, 
at present, there is no metrological traceability above the 
manufacturer’s selected measurement procedure or the 
manufacturer’s working calibrator. In such cases, trueness 
is referred to that level of the calibration hierarchy until an 
internationally agreed reference measurement procedure 
and/or calibrator becomes available” [13]. Furthermore, 
ISO 17511 cautions that “… it is important to recognize 
that different procedures purporting to measure the same 
quantity may in fact give different results when applied to a 
particular sample or reference material. This may arise, for 
example, when two or more immunoprocedures purporting 
to measure the concentration of a hormone such as thyro-
tropin (thyroid stimulating hormone, TSH) are applied to 
a reference material of the hormone, because the respec-
tive reagents recognize and react to different extents with 
various epitopes in the material, thus leading to results for 
different although related quantities” [13].
The immunoassay example mentioned illustrates that 
many variables can contribute to differences among labo-
ratories’ results. These may arise, e.g. from the following:
1. The manufacturer’s product calibrator, which is trace-
able to a given higher order reference material (or 
higher order reference measurement procedure);
2. The laboratory routine measurement procedure 
(method);
3. The source of reagents (same manufacturer or third 
party);
4. The analytical instrumentation used.
The current ILAC policy on the assessment of metrologi-
cal traceability, although released in 2013, lacks any refer-
ence to ISO 17511 or to relevant challenges encountered in 
the documentation of metrological traceability for typical 
measurands in laboratory medicine [11]. Therefore, its use 
as a guideline for the assessment of metrological trace-
ability in medical laboratories may give rise to discussions 
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or even disputes between laboratories and assessors when 
no other documented instructions are provided to the 
assessors that cope with these specific challenges.
To deal with the specific issues concerning measur-
ands of importance in laboratory medicine, the Ameri-
can Association for Laboratory Accreditation (A2LA) has 
published in 2014 a policy on metrological traceability 
especially for medical laboratories, seeking ISO 15189 
accreditation [15], as an additional document to their 
“Policy on Metrological Traceability” [16].
ISO 15189:2012 requirements about 
metrological traceability
With the challenges mentioned in ISO 17511 and the 
specific requirements of the A2LA for the assessment of 
medical laboratories in mind, we will comment on the 
intent of paragraph 5.3.1.4 of ISO 15189:2012 concerning 
“Equipment calibration and metrological traceability” 
[10] in a point by point approach.
“The laboratory shall have a documented procedure 
for the calibration of equipment that directly or indirectly 
affects examination results. This procedure includes: a) 
taking into account conditions of use and the manufactur-
er’s instructions… ”. This is not the first point by accident. 
In medical laboratories, measurements for most tests are 
performed with CE-marked in vitro diagnostics medical 
devices (IVD-MD) (or FDA approved in USA) according 
to manufacturer’s instructions. The new IVD-MD regula-
tion recently released by the European Union Parliament 
states that manufacturers are responsible for establish-
ing and documenting traceability of the commercially 
available assays [17]. Those requirements are now more 
explicitly formulated, as the requirements in the previ-
ous version gave too much room for (unintended) non-
compliance [18]. If clinical laboratories are compliant 
with the manufacturer’s instructions, they only have to 
verify whether the manufacturer properly established 
and specified the traceability data for the used calibra-
tors [19]. Documented procedures should be available 
on how to comply with the manufacturer’s instructions. 
Procedures on how to verify whether the manufactur-
er’s calibration is according to the claimed metrologi-
cal traceability and how to verify that this calibration 
is stable over time are covered by ISO 15189 items 5.5.1.2 
and 5.6.2 on verification of measurement procedures and 
quality control, respectively. Assessment of such pro-
cedures should be performed with regards to those ele-
ments of the standard.
“b) Recording the metrological traceability of the cali-
bration standard and the traceable calibration of the item 
of equipment”. The emphasis in this item is on the word 
“recording”. It does not require “determination”. What is 
asked is that laboratories record the traceability by docu-
menting which higher-order reference in the traceability 
chain is used.
“c) Verifying the required measurement accuracy and 
the functioning of the measuring system at defined inter-
vals”. The “required measurement accuracy” is a term 
from ISO 15189:2012 paragraph 5.5.1 requiring laborato-
ries to select, verify or validate examination procedures 
that meet the criteria selected for the intended use of 
the test. This includes criteria for measurement trueness 
and precision, which together define accuracy. When the 
measuring system fulfil these predefined criteria, it may 
be used in clinical settings. To ensure that the criteria 
are also met in the future, the ISO standard requires veri-
fication at defined time intervals. This may be achieved 
by using data from quality control as required by para-
graph 5.6.2. If quality control results show that accuracy 
or one of its components has worsened since validation 
of examination procedure, but still meets the predefined 
acceptance criteria, the measuring system may be used. 
If the criteria are no longer met, the laboratory have to 
find the cause, implement the corrective action or dis-
continue the method for clinical use if no improvement is 
recorded. This also relates to measurement uncertainty in 
paragraph 5.5.1.4., which is closely linked to traceability. 
Paragraph 5.5.1.4 does not intend calculation and docu-
mentation of measurement uncertainty to be a one-time 
exercise, but to provide data that enables the laboratory 
staff to judge continuously whether a measuring system 
meets the acceptance criteria [20].
“d) Recording the calibration status and date of recali-
bration”. Like the element b), this point concerns the 
recording of information. Calibration is an event that can 
significantly affect results. The purpose of recording all 
calibrations is to be able to reconstruct and audit whether 
the laboratory adequately manages these events. This 
facilitates troubleshooting by the laboratory whenever 
individual or multiple results give rise to doubts about 
their plausibility, for instance because of unexpected dif-
ferences between earlier or later results.
“e) Ensuring that, where calibration gives rise to a set 
of correction factors, the previous calibration factors are cor-
rectly updated”. Laboratory medicine specialists may con-
sider this point trivial, but laboratory staff should always 
be aware of the calibration mechanism used. Before a new 
calibration, laboratorians should make sure that the para-
meters of the equation include the factors of the previous 
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calibration, as the applied calibration curve must reflect all 
the applicable factors to trace the result up to the original 
calibration.
“f) Safeguards to prevent adjustments or tampering 
that might invalidate examination results”. This point is 
repeated in several places in the ISO standard as part of 
management responsibilities for regulating responsibili-
ties and authorization of staff and access control in instru-
ment (analytical platform) software-systems or laboratory 
information systems.
“Metrological traceability shall be to a reference 
material or reference procedure of the higher metrologi-
cal order available”. The most important word here is 
“available”. Other than in physical testing or analytical 
chemistry, in medical laboratory testing the higher met-
rological order available may be the method itself. ISO 
17511 states: “In many cases, at present, there is no met-
rological traceability above the manufacturer’s selected 
measurement procedure or the manufacturer’s working 
calibrator. In such cases, trueness is referred to that 
level of the calibration hierarchy until an internationally 
agreed reference measurement procedure and/or calibra-
tor becomes available”.
“NOTE Documentation of calibration traceability to 
a higher order reference material or reference procedure 
may be provided by an examination system manufac-
turer. Such documentation is acceptable as long as the 
manufacturer’s examination system and calibration pro-
cedures are used without modificatio.”. This note is very 
clear about the intentions of the standard. Apart from 
requirements mentioned in element 5.5.1.2 on method 
verification, there is no need to confirm by experiment 
the information that is provided by the manufacturer as 
long as the measurement system is used according to 
the manufacturer’s instruction. This is in line with the 
A2LA policy for metrological traceability in ISO15189, but 
unfortunately it is totally neglected by the ILAC policy 
P10:2013.
“Where this is not possible or relevant, other means for 
providing confidence in the results shall be applied, includ-
ing but not limited to the following:
 – use of certified reference materials;
 – examination or calibration by another procedure;
 – mutual consent standards or methods which are clearly 
established, specified, characterized and mutually 
agreed upon by all parties concerned”. These sentences 
make clear what should be managed, i.e. the “confi-
dence in the results”. By stating that other means can 
be used, and not limiting the other means to the pro-
vided list, the authors of the standard emphasize that 
the main requirement of the paragraph is to establish 
confidence in the relationship between results and 
their intended metrological traceability.
A role for risk management
The focus on “providing confidence in the results” in 
the last clause is also visible in the first clause where the 
documentation of metrological traceability is limited to 
those calibrations and equipment “that directly or indi-
rectly affect the examination result”. As indicated in 
NOTE 1 of paragraph 5.3 of ISO 15189:2012, “the laboratory 
equipment includes hardware and software of instruments, 
measuring systems, and laboratory information systems”. 
Ancillary equipment, such as pipettes, thermometers, 
CO2 pressure sensors, etc. should be considered as hard-
ware and therefore as part of the laboratory equipment. 
Whether this means that all (or at least some) ancillary 
equipment should have documented metrological trace-
ability is often subject of dispute between medical labora-
tories and assessors. The A2LA offers a practical solution 
by stating that “if a piece of ancillary equipment is not criti-
cal to the result, such as using a pipette to aliquot a sample 
for storage, that ancillary equipment is exempt from this 
policy” [15].
To determine whether a piece of equipment is criti-
cal, ISO 15189:2012 has its own solution in the form of risk 
management as indicated in the 4.14.6 paragraph. There-
fore, the question whether equipment does affect or not 
results should be evaluated on the basis of the severity 
and ease of error detection. A good system of risk man-
agement will differentiate between ancillary equipment 
that needs documented metrological traceability or not. 
Depending on the circumstances of use an identical piece 
of equipment may or may not be prone to such documen-
tation. More in general, risk management can be applied 
all over the standard to resolve questions on choices made 
in required procedures. This ranges from the frequency of 
internal audits to the retention time of documents. The 
standard requires laboratory management to establish 
policies that meet the appropriate need. The only tool to 
establish the appropriate need is risk management.
When we apply risk management to metrological 
traceability in a medical laboratory we start with the 
intention of underpinning the requirement for documen-
tation of metrological traceability, namely transferabil-
ity over time and space. That requires: (1) documentation 
of the traceability to the highest possible reference 
level for a given measurand and (2) periodic verifica-
tion that the documented traceability is still in place. 
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The documentation of traceability should not give rise 
to much ambiguity. The most obvious place to docu-
ment metrological traceability is as a part of the process 
of method verification or method validation. In para-
graph 5.5.1.3 on validation, trueness is listed as a typical 
performance characteristic. As definition of trueness 
requires an anchor to which trueness should be verified, 
it is obvious that only documentation of the metrologi-
cal traceability would provide such an anchor. Medical 
laboratories should document to which higher order 
references the measuring system that they use is trace-
able and the IVD provider will or should provide such 
information. For example, the calibration of a creati-
nine assay can be traceable to the isotope dilution mass 
spectrometry reference method. This implies that IVD 
manufacturers should provide such information in the 
package insert or at least make available upon request. 
In cases where the highest level of the traceability chain 
is the calibration provided by the IVD manufacturer, 
this should be clearly documented. Laboratory directors 
should have in mind the existence of different quality 
among assays for each test due to difference in calibra-
tor measurement uncertainty value and select only those 
products with acceptable measurement uncertainty [21]. 
Assessors have no authority for changing the laboratory 
policy about the chosen measurement procedure. They 
are allowed only to check if laboratory staff reviewed all 
critical data, has selected a method that is suitable for 
the intended use in terms of its performance character-
istics, and informed customers in a proper way about 
all relevant data which might have influenced the test 
results.
Whether the IVD product has a bias compared, e.g. 
to the reference measurement procedure and whether 
this bias is small enough to make the test suitable for 
the intended use is the concern of method verification 
as documented in paragraphs 5.5.1.2 and 5.5.1.3, which 
also check whether the uncertainty including the medi-
cally not relevant bias is acceptable. Tolerance limits for 
allowable bias and imprecision are judged by the spe-
cialist in laboratory medicine in the light of the intended 
use, supported by guidelines of the scientific societies on 
laboratory medicine [22, 23]. Quality control procedures 
as documented in paragraph 5.6.2 should use these per-
formance specifications and check that performance is 
for the intended use as during verification/validation. 
The acceptable bias and imprecision define accept-
able inaccuracy in a single measurement and can be 
expressed as measurement uncertainty [20, 21]. Labora-
tories have procedures for internal quality control (5.6.2) 
and external quality assessment (5.6.3) to make sure 
that their measurement uncertainty does not exceed the 
acceptance criteria of the validation/verification [24, 25].
Measurement uncertainty
The concepts of measurement uncertainty and metrologi-
cal traceability are interrelated. Although the debate on 
how to calculate and express measurement uncertainty 
is – like the fundamentals of metrological traceabil-
ity – outside of the scope of this paper, and depends on 
harmonization by itself [20, 24, 26] we do have to discuss 
its impact on ISO 15189 accreditation assessment. In ISO 
17511:2003, it is clearly stated and graphically depicted 
that each single step of the traceability chain comes with 
its own uncertainty [6, 7]. For the results by the end-user 
procedure at the bottom of the chain, the total measure-
ment uncertainty comprises accumulation of all the 
uncertainties of the chain. This means that the measure-
ment uncertainty of the end user procedure is a combined 
figure that, at least partially, cannot be influenced by the 
end user itself. Braga and Panteghini [24] turn around that 
concept by introducing a budget model where the intended 
use defines acceptable analytical performance criteria for 
measurement uncertainty [21]. This budget of uncertainty 
should be distributed between the individual steps of the 
traceability chain involved. In such an approach the uncer-
tainty of end user procedure is not a result that has to be 
accepted, but a predefined goal that should be achieved 
in dialogue with the higher steps of the chain [20]. Braga 
et al. has proposed that no more than one third of the total 
uncertainty budget, established by appropriate analytical 
performance specifications, is consumed by the uncer-
tainty of reference materials and no more than 50% of the 
total budget is consumed by the manufacturer’s calibra-
tion and all higher steps in the chain [21, 24]. The remain-
ing part of the total uncertainty budget should be available 
for the measuring system imprecision (including the lot 
to lot variation of the reagents) and individual laboratory 
performance to fulfill the uncertainty goal. The new Euro-
pean IVD regulation requires manufacturers to document 
the complete metrological traceability chain as well as the 
between-lot variation in terms of measurement uncertainty 
[21]. Professional IVD users represented by their scientific 
associations, the IVD industry and the national standardi-
zation bodies collaborate in the appropriate ISO technical 
committee (ISO TC212) to formulate definitions on how to 
express the uncertainty of the individual steps of the trace-
ability chain and how to distribute the budget as defined 
by the intended use of the individual tests.
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Conclusions
The main scope of this paper is to encourage ILAC to revise 
its recommended policy for the assessment of metrologi-
cal traceability in medical laboratories seeking ISO 15189 
accreditation. The P10:01/2013 document claims appli-
cability to medical laboratories with ISO 15189 accredi-
tation, but lacks reference to ISO 17511  standard, which 
mentions relevant challenges when documenting metro-
logical traceability in medical laboratories. In particular, 
the accreditation policy should allow for risk mitigation 
by other means that are already obligatory in the accredi-
tation process such as internal quality control, external 
quality assessment and risk management. Meanwhile lab-
oratories and assessors are encouraged to think and act in 
anticipation of the suggested improvements.
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